Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects

以兹提米比 瑞舒伐他汀 药代动力学 药理学 交叉研究 药效学 最大值 医学 瑞舒伐他汀钙 胆固醇 化学 内科学 安慰剂 替代医学 病理
作者
Chang Hee Kim,Hyungmi An,Sung Hye Kim,Dongseong Shin
出处
期刊:Drug Design Development and Therapy [Dove Medical Press]
卷期号:Volume 11: 3461-3469 被引量:17
标识
DOI:10.2147/dddt.s146863
摘要

Background and objective: Rosuvastatin and ezetimibe are commonly applied in lipid-lowering pharmacotherapy. However, the pharmacokinetic (PK) interaction was not clear by the coadministration of rosuvastatin and ezetimibe. This study investigated the pharmacodynamic (PD) and PK interactions between rosuvastatin and ezetimibe through a crossover clinical trial. Subjects and methods: A randomized, open-label, multiple-dose, two-treatment, two-period, two-sequence crossover study with two treatment parts was conducted in healthy male subjects. Study part A involved rosuvastatin, and study part B involved ezetimibe. A total of 25 subjects in both parts completed the PK and PD evaluations. Rosuvastatin (20 mg) or ezetimibe (10 mg) was administered once daily for 7 days as monotherapy or co-therapy. The plasma concentrations of rosuvastatin, total ezetimibe and free ezetimibe were measured for 72 h after day 7. Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC) were investigated for the PD assessments on day 1 (pretreatment) and day 8. Results: Rosuvastatin and ezetimibe presented multiple peaks. The 90% confidence intervals (CIs) of the geometric mean ratios for the peak plasma concentration at steady state (C max,ss ) and area under the plasma concentration–time curve during the dosing interval at steady state (AUC t,ss ) of rosuvastatin and total ezetimibe were within the range 0.8–1.25. However, the coadministration increased the systemic exposure of free ezetimibe. In the PD assessments, rosuvastatin and ezetimibe monotherapy reduced the LDL-C and TC levels effectively. In addition, the lipid-lowering effects of the coadministration corresponded to an approximate summation of the effects of rosuvastatin and ezetimibe monotherapy. However, no significant changes in HDL-C were observed with rosuvastatin or ezetimibe treatment. No significant safety issue was noted. Conclusion: The coadministration of rosuvastatin and ezetimibe revealed a bioequivalent PK interaction. Additional lipid-lowering effects, including decreased LDL-C and TC, were observed as expected in combination therapy without significant safety concern. Keywords: pharmacokinetics, pharmacodynamics, drug interaction, rosuvastatin, ezetimibe

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wyuan完成签到,获得积分20
1秒前
花筱一发布了新的文献求助10
1秒前
Shayne发布了新的文献求助30
1秒前
152455发布了新的文献求助10
2秒前
伊莎贝儿发布了新的文献求助10
2秒前
2秒前
与子同袍发布了新的文献求助10
3秒前
Tuniverse_发布了新的文献求助10
3秒前
Akim的应助被mildjorker采纳,获得10
3秒前
4秒前
科研通AI6.4的应助被Emily采纳,获得10
5秒前
思源的应助被wyuan采纳,获得10
5秒前
5秒前
uizomd完成签到,获得积分10
8秒前
FashionBoy的应助被申晨曦采纳,获得10
9秒前
syvshc的应助被明亮的千亦采纳,获得10
10秒前
keria完成签到,获得积分10
10秒前
和平发展发布了新的文献求助10
11秒前
贺呵呵完成签到,获得积分10
12秒前
12秒前
Jun的应助被迅速雨柏采纳,获得10
12秒前
雪轩完成签到,获得积分10
12秒前
百步穿杨发布了新的文献求助10
12秒前
Iloveyou完成签到,获得积分10
13秒前
我不是马铃薯头完成签到,获得积分10
14秒前
journey发布了新的文献求助10
14秒前
无花果的应助被勤恳如冰采纳,获得10
14秒前
赘婿的应助被mlg1552003采纳,获得10
15秒前
张星星的应助被研小窝采纳,获得10
15秒前
15秒前
16秒前
152455发布了新的文献求助10
16秒前
liangxianli发布了新的文献求助10
16秒前
16秒前
缓慢晓蓝完成签到,获得积分10
16秒前
abin发布了新的文献求助10
16秒前
17秒前
17秒前
玉龙完成签到,获得积分10
17秒前
Cr发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170801
求助须知:如何正确求助?哪些是违规求助? 9563666
关于积分的说明 21771508
捐赠科研通 7762319
什么是DOI,文献DOI怎么找? 3430761
关于科研通互助平台的介绍 2554613
邀请新用户注册赠送积分活动 2475575